Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE).

Hannes CashUrsula SteinerAxel HeidenreichTheodor KlotzPeter AlbersSebastian MelchiorPeter MartusFlorian FullerAhmed MagheliStefan HinzCarsten KempkensteffenKurt Millernull null

Published in: BJU international (2018)

Intermittent docetaxel chemotherapy was non-inferior to continuous therapy for 1-year survival; non-inferiority in regard to OS was not reached.

Keyphrases

phase iii
locally advanced
open label
high intensity
clinical trial
double blind
phase ii
rectal cancer
squamous cell carcinoma
radiation therapy
randomized controlled trial
stem cells
placebo controlled
free survival
bone marrow
cell therapy